- ARO-APOC3 achieved triglyceride reductions of 74-92% - ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% - Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3 PASADENA, Calif. --(BUSINESS WIRE)--Nov. 13, 2020-- Arrowhead Pharmaceuticals, Inc.

- Serum Z-AAT reductions of 86-93% - All patients demonstrated greater than 80% reduction in liver Z-AAT monomer - 3 of 4 patients had a decrease in liver globule involvement - 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68-97% - All patients showed ALT reductions

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 4, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on November 18 , and November 19, 2020 , it will host two key opinion leader (KOL) webinars to discuss the company’s two investigational RNA interference (RNAi) based

PASADENA, Calif. --(BUSINESS WIRE)--Nov. 2, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 23, 2020 , at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2020 .

−        Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD −        Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M −       

PASADENA, Calif.--( BUSINESS WIRE )--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming event: Chardan Virtual 4th Annual Genetic Medicines Conference October 6, 2020, 1:30 p.m. EDT – Vince Anzalone, CFA, Arrowhead’s vice

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020 , the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new

- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values PASADENA, Calif. --(BUSINESS WIRE)--Sep.

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 15th Annual BioPharma Virtual Conference September 9, 2020 – Arrowhead management will participate in